Splenic marginal zone lymphoma: transformation to diffuse large B-cell lymphoma with isolated cerebral manifestation.
Thoennissen
Nils H
NH
Department of Medicine, University Hospital of Muenster, Muenster, Germany.
Keyvani
Kathy
K
Voelker
Hans U
HU
Bremer
Janbernd
J
Krug
Utz
U
Müller-Tidow
Carsten
C
Koch
Peter
P
Müller-Hermelink
Hans K
HK
Berdel
Wolfgang E
WE
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D008223:Lymphoma / Q000473:pathology* / Q000628:therapy*; D016393:Lymphoma, B-Cell / Q000473:pathology* / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D000069283:Rituximab; D013160:Splenic Neoplasms / Q000473:pathology* / Q000628:therapy*; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone